XTLB XTL Biopharmaceuticals Ltd Total Asset Value of Company
XTL Biopharmaceuticals (XTLB) generates revenue by licensing oncology and systemic lupus erythematosus therapies through partnerships with major pharmaceutical holdings. The company's financial foundation is supported by a lack of debt and prudent liquidity management. This chart of the total asset volume, which stands at 0.00, highlights the business's dependence on external financing and the acquisition of new patents prior to reaching the mass-market sales stage.
Analytical breakdowns and data insights for company XTL Biopharmaceuticals, Ltd. (XTLB)
- share price and consensus valuation forecast:
- market capitalization data:
- issuer book value statistics:
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio XTL Biopharmaceuticals|XTLB - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio XTL Bio|XTLB - Company Aggregate Debts|Debts to Book Capitalization XTL Bio|XTLB - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings XTL Biopharmaceuticals|Interim Coverage Ratio xtlbio.com
- net income and valuation multiples indicators:
Fundamental valuation:XTL Biopharmaceuticals
Monitoring the resource base is critical for XTL Biopharmaceuticals (XTLB), an Israeli biopharmaceutical company whose viability depends on clinical trial outcomes and the rate of capital burn. This metric, reconstructed via ROA, measures the aggregate of assets and liabilities, allowing investors to use the company's financial asset volume to filter out accounting anomalies and assess the real scale of the business in the absence of stable revenue.
Key competitors
ARGX (argenx.com) - Aggregate Company Assets|Aggregate Company Assets BioNTech|Abivax - Total Asset Value of Company|Company Total Assets ADMA|PTGX (Protagonist Corp) - Aggregate Asset Value|Company Total Assets IMVT (Immunovant, Inc.)|Company Total Assets kiniksa.com KNSA|GRFS - Aggregate Company Assets|Aggregate Asset Value ADPT (Adaptive Biotech)|Celldex (CLDX) - Aggregate Company Assets|Cumulative Company Assets Aurinia Corp|BCRX (BioCryst) - Company Total Assets|Company Total Assets veratx.com|Cumulative Company Assets DNTH (Dianthus Therapeutics, Inc.)|PHVS (Pharvaris NV) - Aggregate Asset Value|Company Total Assets ABCL (abcellera.com)|Company Total Asset Base Tourmaline (TRML)|PGEN - Aggregate Company Assets|pharming.com (PHAR) - Cumulative Company Assets|Nektar Therapeutics Inc. (NKTR) - Aggregate Company Assets|Cumulative Company Assets Upstream Bio, Inc.|Cumulative Company Assets ZBIO|Company Total Assets Immunome Bio|Aggregate Company Assets Gossamer Bio, Inc. (GOSS)|kalvista.com - Total Business Assets|Company Total Assets SEPN (Septerna)|Pieris Pharma (PVLA) - Company Assets|SVRA: Cumulative Company Assets|RIGL (Rigel Corp) - Total Business Assets|ANAB (AnaptysBio, Inc.) - Cumulative Company Assets|ATXS: Aggregate Business Assets|Aggregate Company Assets enGene|Aggregate Company Assets RAPT|Cumulative Company Assets JBIO (Aerovate Therapeutics Inc)|ACRS (Aclaris Therapeutics, Inc) - Aggregate Asset Value|Company Total Assets KYTX (Kyverna Therapeutics)|tizianalifesciences.com - Aggregate Company Assets|Cabaletta Bio - Company Total Assets|Company Total Asset Base Ventyx Biosciences Inc. VTYX|Theratechnologies Inc (THTX) - Aggregate Company Assets|Company Assets Avalo Therapeutics Inc (AVTX)|Aggregate Company Assets Eledon Pharmaceuticals|agenusbio.com - Total Asset Value of Company|Company Total Assets CLYM|ZURA (Zura Bio Ltd) - Aggregate Asset Value|Company Total Assets ATYR (aTyr)|Company Total Assets Adagene Inc ADAG|IMA - Aggregate Company Assets|Aggregate Asset Value STTK (Shattuck Labs, Inc.)|equilliumbio.com (EQ) - Aggregate Company Assets|Cumulative Company Assets Connect Biopharma Holdings Limited|IMUX (Immunic Therapeutics) - Company Total Assets|Company Total Assets Atara Biotherapeutics Inc|Company Total Assets IFRX|Cumulative Company Assets x4pharma.com XFOR|Company Total Assets ACET (Adicet Bio, Inc.)|Celularity Inc (CELU) - Company Assets|INMB: Cumulative Company Assets|BRNS - Company Total Assets|KZR (Kezar Life Sciences) - Cumulative Company Assets|SABS: Aggregate Business Assets|AKTX (Akari Therapeutics Plc) - Company Total Assets|Enlivex Therapeutics, Ltd. (ENLV) - Company Total Asset Base|Company Total Assets QTTB|Cumulative Company Assets GeoVax Corp GOVX|Company Total Assets EDSA (Edesa Biotech, Inc.)|Company Total Assets ibioinc.com IBIO|CARM - Aggregate Company Assets|BOLT: Aggregate Company Assets|hcwbiologics.com (HCWB) - Aggregate Company Assets|APVO - Company Total Asset Base|Cumulative Company Assets AIM|Total Business Assets ADTX (Aditxt Corp)|Cumulative Company Assets GRI (GRI Bio)|Aggregate Business Assets XRTX|Aggregate Company Assets ReShape Lifesciences HIND|Revelation Biosciences Corp - Aggregate Company Assets|Indaptus Therapeutics - Company Total Assets|SCNI: Aggregate Company Assets|calcimedica.com (CALI) - Aggregate Company Assets|Total Asset Value of Company AFMD (Affimed N.V.)|ALLK (Allakos Inc) - Company Total Assets|HOOK: Aggregate Asset Value|Company Total Assets IGMS|Company Total Assets iteostherapeutics.com (ITOS)|Aggregate Company Assets Ocean Biomedical OCEA|Aggregate Asset Value TCBP|THRD - Aggregate Company Assets